The association between pancreatic cancer and GLP-1 RA and DPP-4 inhibitors is not as clear, with some studies showing that they may increase the risk of developing pancreatic cancer due to overstimulation of the GLP-1 receptor and an increased risk of pancreatitis. Here, GLP1R is linked to pancreatic neoplasm.